NTT
18.12.2019 07:55:13 CET | Business Wire | Press release
In recent times, there has been a growing demand for companies worldwide to strengthen their compliance and risk management. To help our clients manage these requirements, NTT Group, represented by NTT Advanced Technology Corporation (hereinafter, NTT-AT), Everis Spain S.L.U. (hereinafter, everis) of NTT DATA Corporation, itelligence AG (hereinafter, itelligence) of NTT DATA Corporation are announcing a compliance management solution using robotic process automation (RPA). This solution aggregates and analyses data from internal HR and compliance on-premise and cloud-based systems, supporting customer initiatives to strengthen responsibility and internal governance control. The NTT Group plans to start providing this service in the second quarter of 2020.
Due to stricter regulations across many industries, particularly the financial industry, businesses are facing the threat of multi-regime controls and high fines by local authorities. Due to the complexity of the regulations and reporting requirements, these institutions are facing problems to identify compliance issues, along with a lack of transparency in governance. This often leads to increased manual workload, process time and paperwork due to the complexity of their IT environment.
The integrated solution provided by NTT Group combines; the RPA tool "WinActor ® (*1) " of NTT-AT, the SMCR solution of everis, and the consulting and the integration capabilities of itelligence to achieve the combination of reducing complex manual operations and coordination of compliance-related data managed across multiple systems, such as Excel (*2) and existing systems.
This solution will initially be provided as a compliance management solution for the “Senior Managers and Certification Regime (SMCR)" in the UK and will be expanded outside the UK in response to regulations and to support clients compliance and governance management globally.
NTT helps its clients accelerate their digital transformation journey by implementing innovative technologies, such as WinActor® .
Notes:
About "WinActor®
"
WinActor is a robotic process automation (RPA) tool which has been developed using the in-house technologies by NTT Access Network service system laboratories and has been achieved into commercialization.
WinActor records and automates various types of human operations such as those via Windows (*2)
application, Web Application and so on. It runs automatically routine repetitive tasks and large volume works instead of or collaborating with human. Additionally, by changing the existing jobs into new automatic work style, it would bring out a large value in business perspective such as efficiency, quality and cost effectiveness without modifying any software of existing system.
WinActor has been rapidly introduced and spread since 2017 especially in the organizations which seek for “Work style revolution” regardless the type of industry and size of the company. Currently, in November end of 2019, more than 4,200 companies have introduced WinActor.
For more information, please refer to https://winactor.biz/
.
(*1) "WinActor" is a registered trademark of NTT Advanced Technology Corporation.
(*2) "Excel", “Windows” is registered trademarks or trademarks of Microsoft Corporation in the US and/or other countries.
About NTT
For more information on NTT, visit www.global.ntt/
For more information on NTT-AT, visit www.ntt-at.com/
For more information on everis, visit www.everis.com/global/en
For more information on itelligence, visit itelligencegroup.com/us/
For more information on the solution, visit uk.nttdata.com/SMCR
View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005950/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom